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Degree of Master of Science
(in Biomedical Engineering)
August 2022
Although breast cancer is a growing health concern worldwide, the challenge to minimize
mortality rate partly comes from the heterogeneity in its pathological characteristics. The tumor
microenvironment is a complex hub of signaling cascades that plays a key role for the
progression of cancer to develop to metastatic stage. The extracellular matrix (ECM), as a major
component of the tumor microenvironment, contains signatures that have cues to understand
tumor progression. Here, the unique microstructural collagen alterations specific to reactive
stromal/tumor cell interactions and interactions of reactive stromal fibroblasts with different
tumor cell types MCF7A and MDA-MB-231 were investigated. Early alterations of collagen
were characterized using the label free, collagen specific, multiphoton laser scanning imaging
modality known as Second Harmonic Generation microscopy (SHG). The directionality effect of
SHG, calculated as the ratio between the forward and backward SHG (FSHG/BSHG), is used to
characterize the different collagen signatures locally at 10-pixel (3.52μm) dilation from the cell
boundaries. Activated fibroblasts remodel collagen differently resulting significantly higher
FSHG/BSHG than deactivated fibroblasts and Wilcoxon rank-sum test gives p<0.05 showing
the

statistically significant difference. The gels where stromal activated fibroblast and MCF7A
cancer cells were interacting resulted a significantly lower FSHG/BSHG ratio than collagen gels
where stromal deactivated fibroblast were co-cultured with MCF7A cancer cells. The Wilcoxon
rank-sum test shows the statistically significant difference (p<0.05) in their FSHG/BSHG ratio. The
remodeling effect of MDA-MB-231 cancer cells when they interact with stromal activated
fibroblast had skewed higher FSHG/BSHG ratio than when interacting with deactivated fibroblasts.
The MDA-MB-231 samples do not have a statistically significant difference (p>0.05) in their
FSHG/BSHG ratio.
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INTRODUCTION

The tumor microenvironment is a complex hub of signaling cascades. Stromal cells are
80% of the tumor microenvironment and tumor microenvironment is 90% of the solid tumor
mass.1 The organization of collagen fibers in the tumor microenvironment plays a significant role
in tumor progression. Cancer Associated Fibroblasts (CAFs) in the tumor microenvironment are
involved in modifying ECM protein and providing cancer cells with structural signaling. CAFs
are also involved in inducing organizational changes in collagen fiber microstructure.
Understanding the underlying mechanism of fiber organization that contributes to metastasis is
crucial. The interaction between stromal and tumor cells in reactive and normal conditions give
an in depth understanding of ECM remodeling that aids tumor metastasis. In this thesis the
questions asked include are their unique microstructural collagen alterations specific to reactive
stromal/tumor cell interactions? Digging deeper, are the interactions of reactive stromal
fibroblasts dependent on the tumor cell type? To answer these questions the stromal/tumor cell
interactions were modeled by the in vitro collagen gels prepared as described in the following
section.
Advancements made in modern microscopy especially nonlinear optics made it possible
to carry out different biological research. The nonlinear optical process that is used to
characterize the different collagen microstructural alterations quantitatively is second harmonic
generation microscopy (SHG). SHG is a collagen specific multiphoton imaging technique in
which signals are generated from the intrinsic properties of collagen molecules. The
directionality effect calculated as the forward/backward (FSHG/BSHG) ratio is used to analyze
remodeled collagen quantitatively.

ix

Biological image analysis in recent years has been advancing to allow the extraction of
the maximum information from a biological sample image. Image segmentation as part of the
image analysis, is used to separate features in the image of the biological sample for region of
interest or bulk analysis. In this thesis work an image analysis pipeline is developed to segment
cell fluorescence images and to calculate the FSHG/BSHG ratio at regions of interest. This thesis
provides a simple image analysis technique that couples pixel-by-pixel cell segmentation with
object segmentation that can be adopted easily. Additionally, the FIJI macro that was made in
this thesis presents a simple way to quantitatively assess specific regions of interest without
needing to worry about background pixel values. Ultimately, this work provides the outline of
challenges in breast cancer, interactions of different stroma/tumor cell, image analysis developed
to quantify the biological change, and review for the possibility in SHG commercialization for
clinical use.
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CHAPTER 1
BACKGROUND
1.1 Breast cancer worldwide
Breast cancer is the second leading cause in cancer related death and the most dominant type
of cancer in female. According to a 2020 report by GLOBOCAN and the World Health
Organization (WHO), breast cancer has the highest incidence rates of all cancers in 159 of the
185 countries observed.2–4 Moreover, WHO ranked all kinds of cancers to be the current leading
cause for a minimal life expectancy in many countries worldwide.5 The worldwide 2020 cancer
record shows that out of the estimated 19.3 million new cancer cases, 24.5% of it is comprised
by breast cancer and from almost 10 million cancer death female breast cancer contributes 15.5%
of the incidence (see Figure 1).2,6 In the United States, in particular, the American Cancer
Society has promoted early cancer detection campaigning using simple self-examination and
clinical breast exam since 1930s.7 Following the recognition of mammography as a breast
screening technique in the 1950s, the American Joint Committee in Cancer determined staging
classifications.8 The increased early cancer detection campaign improved the access women had
for advanced clinical breast examination. The escalation of breast cancer diagnosis since the
1980s, increased the number of diagnosed women and showed a very small change in decreasing
the mortality rate. 9,10 Interestingly, the highly promoted early detection techniques did not
significantly reduce the mortality rate in the US as the graph from the analysis on the incidence
and mortality rate between black and white female shows (see Figure 2). This difference in
survival between the two race comes from access for early detection, follow up rates, and
pathological differences in the breast cancer subtype. The probability of black female being
diagnosed with triple negative breast cancer subtype and being diagnosed with beyond stage I
breast cancer resulted in a higher mortality rate than white female.11
1

Figure 1: The 2020 GLOBOCAN Pie Chart on the most common cancer types in female
represents the total number of new cases (A) and deaths (B) recorded worldwide. Again in 2020,
breast cancer accounts for majority of both the new case (2.3 million) and death (0.68 million)
records out of all the different cancer types. Breast cancer has shown persistency in being leading
cancer incident around the world. 2
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Figure 2: Female breast cancer incidence and mortality rate studies for White (including
Hispanic) females vs black (including Hispanic) females between 1975-2018 shows that
incidence rates for White female are higher than Black female however, the mortality rate for
Black female is higher by 39% than White female. In general, mortality rate has not shown
change in the rate since throughout the years of diagnosis.10
Globally WHO organized several early detection campaigns to minimize the total number of
young and adult women that are dying from breast cancer. The report released by GLOBOCAN
in 2018 shows the number of incidence and mortality rate for women age groups of 45+ and 45in high, high middle, low middle, and low income countries.12 As shown in Figure 3, higher
income countries have increased number of women that get diagnosed in both age groups
compared to low income countries. However, the death record for both age groups is consistent
in all income countries. Furthermore, in that same year, WHO started promoting early diagnosis
and clinical breast examination through screening for all women worldwide, especially in
3

developing countries for better patient prognosis.13 Along with this early detection campaign,
WHO also implemented step by step plan for clinical based examination and treatment.
Nonetheless, in low middle- and low-income countries where it is difficult to perform these
strategies routinely, it is hard to make any population-based claim on the efficiency of the early
cancer detection techniques. Moreover, in these developing countries the coupling effect of early
detection and treatment has on breast cancer incidence is limited by several factors. Whereas in
higher income countries where women have access to routine screening and other clinical breast
examination, the efficiency of early breast cancer detection campaign is visible through the
increased incidence rate (Figure 3).

Figure 3: The 2018 GLOBOCAN age adjusted rates of breast cancer analysis worldwide
comparing incidence and mortality rates among older age (45+) (A) and younger age (<45) (B)
female shows consistency in the mortality rate in all the different countries of varied income.
However, incident rates are higher for both age groups in high income countries than lowincome countries. 12

4

Although breast cancer is a growing health concern worldwide and several early detection
methods are being advertised, it is very heterogeneous in its pathological characteristics.14 Breast
cancer, in general, develops in several stages as shown in Figure 4A. The stages are classified
clinically based on tumor size (T), nodal status (N), and metastasis (M). TNM classification is
used to determine the degree of the cancer spread from local to distant using either pathological
stages (performed by examining a tissue removed during surgery) or clinical staging (based on
physical exam, biopsy, or screening).15,16 The survival rate for women with breast cancer varies
with the different stages. Studies showed that out of all breast cancer cases 20%-30% are most
likely to grow into a metastatic stage and >90% of breast cancer related death is caused by
secondary metastasis.17,18 The American Cancer Society, in its 2021 report presented the 5-year
relative survival rate for the different stages as shown in the table in Figure 4B. In some breast
cancer cases if the women are able to get the needed diagnosis and treatment, they have a better
prognosis unlike some breast cancer cases that do not have a promising prognosis despite the
treatment. Prognosis rate for women depends on the breast cancer subtype in which the poorest
survival rate is seen among women with triple negative subtype.19
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Figure 4: Stages of breast cancer (A) and the survival rate at the different stages (B)20. Survival
rate decreases as the breast cancer develops into the metastatic stage. (C) breast cancer survival
percentage for a period of months depending on the metastatic site. 18
6

The Breast Global Health Initiative developed a framework for middle- and low- income
countries to have access to better treatments following clinical diagnosis to minimize mortality
from late-stage breast cancer.21–24 Despite the work to improve breast healthcare in these
developing countries factors ranging from economy to cultural beliefs still this day have
implications on the survival rate in many areas. The promotion to educating women on
developing the habit for early age breast examination and better life style in developing countries
has been recognized as a crucial tool to reducing the number of women diagnosed for late stage
breast cancer.25 On the other hand, in developed countries there is an increased rate in
availability of breast cancer treatments for each stage and every breast cancer subtype. The
adequate detection and treatment resources that women in developed countries have access to,
significantly improved the 5 year survival rate.26 Contrarily, in developed nations overdiagnosis
and overtreatment has been a growing concern for the oncology team.27,28 Many women are
getting overtreatment for earlier stages mainly because of patient’s fear of dying cancer and
doctor’s fear of cancer progressing to latest stage. These administered early-stage treatments that
are more than what patients clinically need, add complexation on the health of the women as
well as economic burden.28,29 Especially in stage IV, due to the spread of the cancer to several
locations a more specific location focused treatment may not be enough. Treatments for this
stage depend on the secondary site where the tumor cells migrated to and the tumor molecular
sub-type.30,31 Overall, even if the currently existing breast healthcare advancement is showing
high incidence and mortality rate, the administered treatments are not effective to significantly
reduce mortality rate. In this thesis we focus on understanding the tumor microenvironment for
the identification of more effective therapeutics.
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1.2 Tumor Microenvironment
1.2.1 Extracellular Matrix
The extracellular matrix (ECM) is the non-cellular component of tissue and it is
composed of two main compartments which are the basement membrane and the interstitial
space.32,33 Both entities have their own components to complete their task. The basement
membrane is a thin membrane that contains collagen IV, laminins, fibronectin, and other
fundamental molecules.34 The interstitial matrix contains collagen, fibronectin, elastin, decorin,
and hyaluronan.33 In general, ECM is composed of the two main macromolecules proteoglycans
and fibrous proteins.35,36 This complex network in the ECM provides cells with the essential
biochemical and biomechanical cues. Stromal cells produce and assemble the extracellular
matrix to help in modulating the function and behavior of the cell.37 The unique and specialized
components of the ECM regulate tissue integrity, cell-cell connections, interactions, and
communication.38 ECM signaling in the breast tissue is tightly regulated for the development of
mammary glands. If the degree of stiffness, organization, and molecular composition of ECM is
altered then the cell environment may be affected as the physical assembly state of ECM is
critical to cell response and function.39,40
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Figure 5: The extracellular matrix (ECM) is the non-cellular component of any tissue that
provides the essential biochemical and biomechanical cues. ECM is composed of many
proteoglycans and fibrous proteins. [Modeled after Pompili et al. (2021)] 33
Stromal cells are 80% of the tumor microenvironment and tumor microenvironment is
90% of the solid tumor mass.1 ECM composition in breast cancer environment facilitates in the
progression of cancer. Studies have shown that the remodeling of the ECM in breast tissue
highly contributes to the progression of breast cancer.41 Breast cancer researchers have been
focusing on ECM to study the tumor microenvironment in depth to investigate the interaction
between cancer cells with different ECM components. Careful analysis of the ECM protein
signaling pathway involved altering the tumor microenvironment, may aid in the production of
promising thereapeutics.42,43 In the tumor microenvironment, ECM has different signatures that
contain valuable information on understanding tumor progression and metastasis. The tumor
microenvironment is very heterogenous. Depending on the tumor sub-types, there are different
signaling cascades that occur between the primary tumor and stromal ECM components to aid
tumor progression to metastatic site.44 The extracellular matrix provides the cell-to-cell adhesion
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for tumor cells to move by creating means for direct contact between collagen and cancer
associated fibroblasts. Different breast cancer sub-types migrate to different secondary locations
by employing ECM components to favor their work.45–47 As shown in Figure 6, the different
signatures in the ECM are results of the cross-talk between the stromal cell components and the
cancer cells in the primary location succeeding to more remodeling of ECM for cell migration
(as shown in Figure 7).48 In this research, different ECM signatures resulted from remodeling by
decidualized fibroblasts and cancer associated fibroblasts are studied.

Figure 6: Step by step mechanism of the remodeling of ECM created by the communicating
cancer cells and tumor-associated stromal cells in the primary tumor location. The crosstalk
between ECM proteins and cancer cells contributes heavily on the support that stromal cell has
for cancer cells. [Adopted from Winkler et al. (2020)]48
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Figure 7: A. Carcinoma in situ, tumor cells communicate with ECM components, but are
restricted from migrating into the surrounding tissue. B. Tumor cells and cancer associated
fibroblasts communicating via integrin for proteolytic degradation of ECM to achieve the
breakage of ECM basement membrane. C. Crosstalk between the cancer associated fibroblasts
and tumor cells degrades the basement membrane and reorganizes collagen fiber for tumor cell
migration. [Adopted from Winkler et al. (2020)]48

1.2.2 Collagen molecule assembly
One of the major components of ECM is collagen, which is the most abundant fibrous
protein in connective tissue. Collagen has a tissue specific hierarchical organization (as shown in
Figure 8B) consisting of three polypeptide chains, α-chains. The α -chains contain varying size
of amino acids forming multiple α-chain types which then twists to form the major collagen
structural component, the triple helix (its amino acid sequence domain is Gly-X-Y).49 Formation
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of type I collagen starts with three α-peptide chains, two α-1 & one α-2, self-assembling to
procollagen then the two peptide ends get removed by enzymes in the ECM to form
tropocollagen, the triple helix.50 The carbon-oxygen and hydrogen-nitrogen bonds comprising
the α-helix has their own dipole moment which then is amplified along the peptide chain giving
the collagen molecule a permanent dipole (as shown in Figure 8A).51 The basic structural unit of
collagen, the triple helix tropocollagen, group together through self-assembly into fibrils then
bundle up into collagen fibers.51–54 Collagen is present in the interstitial space of the ECM along
with many other fibrous proteins and it also develops to different collagen types i.e. collagen II,
III, IV.

Figure 8: A. Collagen molecules have a permanent dipole.[Adopted from Robinson et al.
(2016)]50 B. Hierarchical organization of collagen fiber.
Collagen in normal tissue reorganizes for functions such as wound healing. In breast
tissue, higher collagen deposition results in dense tissue increasing risk of breast cancer.55 Tumor
associated collagen signature (TACS) show significant difference in their alignment depending
on their progression state in which dense collagen indicating presence of smaller tumor,

12

stretched fiber around the tumor boundary indicating tumor growth, and radial fiber alignment
indicating possibilities for tumor invasion (Figure 9).56 Investigating the stromal cell in the
complex tumor microenvironment for tumor associated collagen signatures aid in patient
prognosis.17,43,57,58 Improved understanding of this environment is critical for development of
better therapeutics that could possibly block the cross talk in the complex tumor
microenvironment to improve breast cancer survival rate. Here in this thesis collagen signatures
resulting from microstructural remodeling caused by the interaction between reactive or nonreactive stromal/tumor cells were quantified using a collagen specific imaging modality.

13

Figure 9: A. In tumor associated collagen signature -1, the dense collagen surrounding the tumor
is characterizes by higher intensity in signal and indicates the presence of small tumor as outlines
by the yellow curve. B. In tumor associated collagen signature-2 majority of the collagen fiber
are characterized by having parallel orientation to the tumor boundary. C. In tumor associated
collagen signature-3 collagen fiber has irregular distribution around the tumor boundary,
however, fiber orientation is mainly characterized by showing a perpendicular alignment to the
tumor boundary.[Adopted from Provenzano et al. (2006)]56

1.2.3 Fibroblasts
Like collagen, fibroblasts are also most common cells in connective tissue. They are
major component of the ECM as they produce and reorganize ECM proteins for normal tissue

14

function.59 Fibroblasts engage in tissue modification and production of different ECM proteins
such as collagen, proteoglycans, fibronectin, glycosaminoglycans and other glycoproteins.60,61
Fibroblasts are elongated cells that are key for collagen synthesis. They communicate with the
surrounding ECM components using different mechanisms and not considered to be active
remodelers of the ECM microenvironment.62 Myofibroblasts, here modeled using decidualized
fibroblasts, are activated fibroblasts in non-cancerous stromal cell that are mainly involved in
wound healing.63–65 In their activated format fibroblasts are characterized by higher α-smooth
muscle actin expression and greater production ECM protein along with intense
remodeling/reorganization of collagen. Due to this remodeling, there is an extensive stress in the
fiber network until the location restricted wound healing or specific job is accomplished. The
process of wound healing and remodeling for cancer cell progression by cancer associated
fibroblasts have similar underlying mechanism.

Figure 10: Stromal inactive fibroblasts (a) and stromal activated (b) fibroblasts surrounded by
collagen fiber and other ECM components. [Adopted from Kalluri et al. (2006)]66
Cancer associated fibroblasts (CAFs) share similar characteristics as the wound healing
process. However, they are different from the normal stromal activated fibroblasts such as
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myofibroblasts because they are characterized by increased production of ECM protein and
collagen. The tumor microenvironment is very heterogenous in its nature and the extra ECM
proteins produced by CAFs provide the cancer cell with structural signaling. Orientation of
collagen fibers influences directed migration of cells by either potentiating growth factor
receptor signaling or by mechanically reinforcing cell migration.67 The remodeling by CAFs
could enhance metastasis as the mechanical cues between CAF and the tumor increase the
stiffness of the surrounding matrix. Cancer cells communicate with their surrounding
environment through different signaling cascades. The mechanoreceptors that are highly
associated in the transmission of information between CAFs and cancer cells in a tumor
microenvironment are integrins.68 Integrins, specifically the α,β-integrin subunits, are noncovalently linked heterodimers that transduce signals for the communication between CAFs and
cancer cells in the tumor microenvironment.68 These integrin subunits are expressed by both
stromal ECM and cancer cells in which the cell-adhesion mechanical communication has strong
contribution for the cancer progression to metastasis.69,70
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Figure 11: Tumor microenvironment (TME) contains cancer associated fibroblasts (CAFs)
which are characterized by increased production of the ECM protein. Increased synthesis,
degradation, and remodeling of fibrillar collagen in the ECM aid cancer metastasis.[Adopted
from Jang et al.]68
As studies show, tumor associated collagen signatures can serve as a biomarker for the
different stages of tumor metastasis and perhaps in determining the survival rates of breast
cancer patients.71 Understanding the underlying reasoning for tumor metastasis could also help in
studies for potential therapeutic development to block tumor metastasis. The ability to view
collagen organization in a tumor environment with sub-micron resolution to quantify collagen
fiber organization is critical. Researchers have been employing several optical techniques to
investigate the orientation of fibrillar collagen caused as a result of this increased remodeling in
the tumor microenvironment.72–74 In this work, two-photon excitation fluorescence microscopy
for cell autofluorescence imaging and second harmonic generation microscopy for collagen fiber
imaging are discussed as an outstanding imaging modality for tumor microenvironment study.
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1.3 Instrumentation
The microscope is a ubiquitous instrument used in biomedical science and engineering.
Optical instruments could be designed in several different ways to fit the appropriate task. The
history of optical instruments, mainly microscopes, dates back to the 16th century but, it was first
introduced to biologists after Robert Hooke viewed cells.75,76 The development of microscope
started from a simple microscope comprised of a single lens. Since then, microscope underwent a
significant modification to a more complex design so that optimized resolution is achieved, and
aberration is minimized. The development of modern microscope has accelerated the study of
life science.
Many researchers use different microscopy techniques to investigate cell extracellular
matrix (ECM) such as wide-field fluorescence microscopy, confocal microscopy, and nonlinear
microscopy. In recent years nonlinear laser scanning microscopy is highly selected to study the
ECM over the other microscopy techniques due to its advantages for deeper penetration in
thicker samples, less photobleaching, intrinsic optical sectioning, higher spatial resolution, and
ability to collect endogenous information.77,78 Nonlinear laser scanning microscopy significantly
enhanced the study of collagen structure in disease and normal states. The two nonlinear optics
that are highly utilized to study the organization of collagen fiber in cancerous environments are
two-photon microscopy and second harmonic generation microscopy.79,80,81 Both optical
techniques have their own mechanism of revealing the details in the unseen microscopic
phenomenon. The fundamental parts for the light pathway from the source to sample then to a
detector for both these techniques is similar except the emission filter. In this work, the specific
components of these nonlinear optical techniques in their application to study TACS is
explained.
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1.3.1 Instruments used in Collagen imaging
1.3.1.1 Fluorescence Microscopy in ECM and collagen imaging
In the 1800s and early 1900s the phenomenon of fluorescence was highly investigated.82
Alexander Jablonski graphically described the energy states of fluorescence in what is known
today as a Jablonski diagram.82,83 The graphical description of the absorption and emission
patterns of light in the Jablonski diagram advanced the knowledge of fluorescence. Then later the
invention of lasers in the 1960s advanced the development of fluorescence microscopes and set
the stage for the invention of laser scanning microscopes.84 Soon after Carl Zeiss introduced the
first laser scanning fluorescence microscopy in 1982.82 The production of pulsed lasers advanced
the development of nonlinear microscope techniques such as the two-photon fluorescence
microscopy and second harmonic generation microscopy. The advancement in the production of
lasers, lenses, objectives, mirrors, filters, and detection methods in the later years enabled
researchers to design and build homemade multiphoton microscopy techniques.

1.3.1.2 Two photon excitation fluorescence microscopy
The first theory of the two-photon process was made by Gopper Mayer with the first
experimental observation of the process in 1961. The introduction of pulsed lasers was a great
contribution for the advanced development of the multiphoton microscopy system. Since then,
multiphoton laser scanning microscopy (MLSM) has become a useful field under the nonlinear
optical microscopy for biological studies.85,86
The two-photon process, unlike a single-photon process, requires two photons to
simultaneously excite a molecule from its ground state. In a single-photon process a shorter
wavelength is mostly used to provide sufficient energy for the molecules, however, in a twophoton process a longer wavelength is used. There are several advantages to using a longer
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wavelength in the two-photon excitation process such as deeper penetration in thicker samples,
minimal photodamage, high spatial resolution, ability to deeply investigate components in highly
scattering biological sample. These advantages come from the fact that energy and wavelength
are inversely related.

Figure 12: Jablonski diagram of one-photon (A) and two-photon (B) fluorescence processes. In
one photon fluorescence only one photon of shorter wavelength is absorbed by fluorophores to
get to excited state from the ground state. In two-photon fluorescence, a longer wavelength is
used to excite fluorophores and unlike one photon here two photons are simultaneously being
absorbed by fluorophores. [Adopted from So, P.T et al (2001)]87
The underlying physics of two-photon excitation fluorescence microscopy (TPEF) rely
on the fluorophore's ability for a two-photon absorption cross-section. The two-photon
absorption cross-section is the measure for the probability of the absorption process by intrinsic
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or exogenous fluorophores. Illumination process in two-photon process is pulsed in which the
molecule’s ability for simultaneous absorption of two photons of half the excitation wavelength
double the frequency at a reduced energy is critical (see Figure13). Since two-photon
fluorescence is a nonlinear process, the intensity of the emission signal is the square of the
irradiating signal.79As shown in the Jablonski diagram in Figure 13, two-photons at a given
frequency and wavelength get absorbed by a fluorophore to produce one photon of less than
twice the frequency and less than half of the incident photons.

Figure 13: Two-Photon Excitation Fluorescence Jablonski Diagram. [Adopted from Masters
2010)]82
In 2PEF microscopy the key components are a mode locked femtosecond pulsed laser
(mostly Titanium-Sapphire laser), an objective lens, dichroic mirror, bandpass filter, and photon
counting head.88 During objective lens selection the important specifications to consider are the
magnification, the numerical aperture, the working distance, and its efficiency in excitation
signal collection. When choosing a collection optics, it is important to consider their collection
efficiency. Quantum efficiency, response time, wavelength sensitivity, and linearity are
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important things to balance on a PMT. The considerations needed to take when selecting laser
are the pulse width, peak power, repetition rate, and wavelength tunability range.89

1.3.1.3 Second Harmonic Generation Microscopy (SHG)
Second Harmonic generation (SHG) has been around since 1974 after the introduction of
pulsed lasers but for the last two decade SHG has been highly utilized in biological research.80
SHG is also a nonlinear optical and the Jablonski diagram below shows the SHG process. SHG
was introduced as the nonlinear biological sample imaging technique in 1986 after its first
publication as a nonlinear technique in 1978.90 In SHG there is no absorption and emission rather
signals are generated from the intrinsic property of the molecules in the biological sample which
have non-centrosymmetric order. The lack of symmetry in the assembly of collagen molecules
makes it compatible with the physics of SHG signal generation. SHG as a nonlinear process also
permits deeper penetration in thick sample imaging with intrinsic optical sectioning.
Furthermore, in SHG there is no photobleaching and phototoxicity since it is mostly based on
scattering rather than absorption.
SHG is also a coherent process that is dependent on the dipole organization of the
molecules in the order of the SHG wavelength. SHG has directionality in which a specific signal
pattern comprises the forward and backward propagating components. The characterization of
the emitted signal for SHG is determined by the phase matching of signals emitted from
individual molecules. SHG contrast is dependent on the orientation of the molecules in the
microstructures in the direction of the laser propagation and the polarization of the incident
beam. Mathematically the relationship between the polarization, the ability of the molecule to
generate second harmonic signals (linear susceptibility), and the electric field is defined as
P(t)=X (2) E2(t)
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where P(t) is the polarization at time t resulting from the dipole moment of the molecules within
a certain volume, X(2) is the second order susceptibility tensor, and E is the electric field.

Figure 14: Second Harmonic Generation Jablonski diagram (Left) showing two photons of half
the frequency twice the wavelength interacting with a non-centrosymmetric medium to produce
one photon of double the frequency but half the wavelength of the incoming photon. The
fundamental of SHG is its directionality which is dependent on the dipole organization of
collagen molecules in the order of λSHG within the optically nonlinear medium (Right). [Adopted
from Mostaco-Guidolin, L. et al (2017)] 54
The fundamentals of SHG are its directionality and phase matching which is used to
characterize the different collagen architecture. Phase matching of the half frequency and double
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frequency in SHG must be in phase so that they do not destructively interfere. In an ideal noncentrosymmetric medium, SHG signals are strongly forward directed and mostly remain in
phase. However, in biological structures such as collagen, it has been known that there are both
forward and backward signals.91 SHG signals in collagen imaging arise from the dipole moment
in the alpha helix. Fibrillar assembly ordered at the size scale of SHG wavelength are mainly
forward directed. However, the inherent properties of collagen molecule organization does not
result perfect phase matching. The presence of the difference in order, size, and shape present in
collagen molecules in disease and normal states contributes to the signals phase-matching.92–94
For this reason, SHG is anisotropic. The directionality effect of SHG can be quantified by
calculating the forward propagation by the backward propagation (F /B ) and the phaseSHG

SHG

matching consideration can mathematically be expressed as follows.

The physical property of SHG that is needed to answer the desired question is its phase
matching. Unlike 2PEF signals SHG signals are produced from the interaction between the
incoming photon with the non-centrosymmetric medium instead of molecules absorbing and
emitting signal. The presence of the difference in order, size, and shape present in collagen
molecules in disease and normal states contributes to the signals phase-matching. The signals are
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produced without the presence of any exogenous material which gives intrinsic information of
the collagen molecule assembly.
SHG signals are produced strongly in the range of 800nm to 890nm as seen in most
biological research.95,96 In this work the mode locked Ti-Sapphire pulsed laser was used. This is
a pulsed laser unlike a continuous laser it emits light at a repetition rate which describes the
frequency in which pulses are emitted. The use of pulsed laser accommodates the probability for
the simultaneous arrival of the smaller energy photons at the sample for signal generation.97 The
time measured across the pulses is known as the pulse duration in which shorter pulse duration
with high peak power deliver minimal heat to the sample also decreasing photodamage on the
sample. The pulse width, a measure of the time between the beginning and end of the pulse,
affects the average power in a directly antagonist manner for a given period. The period
describing the time between the start of one pulse and the start of the next pulse, relates to the
average power inversely. Therefore, increasing pulse width of the laser beam while decreasing
its period, increases the average power. Overall, a smaller pulse duration with a higher average
peak power is a preferred feature for the nonlinear process and deeper penetration in thick and
highly scattering samples.88
In the excitation pathway, the important components to consider are the half wavelength
and quarter wavelength waveplates, the scanning head, dichroic mirror, and the objective. The
half wavelength (λ/2) waveplate holds the polarization of light by a half wavelength and changes
its linear polarization direction. The quarter wavelength (λ/4) waveplate holds the polarization
light by a quarter of the wavelength and converts it from linear to circular polarization. The
scanning head, to be used along with an upright microscope, has two channels that is used for
both the forward and backward signal emission. The dichroic mirror used on the way of the laser
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beam before it gets to the objective is selected based on its higher transmission efficiency for the
near IR wavelength and higher reflection efficiency for the SHG wavelength. An objective with
features such as water immersion, high Numerical aperture (NA), low magnification, and longer
working distance along with a better transmission efficiency of the near-IR wavelength is
selected for the design. Selecting a high NA low magnification water immersion objective
corrects spherical aberration and it is useful for a higher resolution.
The forward and backward emission pathway must contain the components dichroic
mirror, lenses, SHG filter, a Photo-multiplier tube, and detection mechanism. The dichroic
mirrors are selected based on their ability to reflect emitted light at the SHG wavelength to the
detection pathway. The lenses on the way of the emission focuses the signal that goes to the SHG
bandpass filter. From the bandpass filter the signal goes to a photon counting head which couples
a photomultiplier tube (PMT) with a built-in optimization system. As the received photon signal
goes through the PMT it gets changed to a current with a higher electron gain. The output
measurement done in a photon count mode gives a better signal to noise ratio. Details of the
specific parts used in the design are further explained in chapter 2.

1.3.1.4 SHG competitive ECM imaging modalities for clinical use
PolScope is an imaging alternative for collagen imaging that can be used in place of SHG
and regular staining. PolScope unlike the regular polarization microscope uses a Liquid Crystal
(LC) compensator that eliminates the physical moving of specimens to find birefringence in the
sample.98 Collagen being a highly birefringent component of the ECM (although there are other
birefringent in the ECM collagen is highly dominant), it is suitable for the LC-PolScope imaging.
The orientation and alignment of collagen in a smaller sample can be studied using the PolScope
without requiring any staining and any higher optical complexation for any pathological studies.
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Studies have also shown that quantitative assessment of collagen alignment and orientation
completed on images taken by both LC-PolScope and SHG show a higher correlation. The
advantage of LC-PolScope over a traditional Polarization microscope lies in the fact that any
orientation scale in the fibrillar organization of collagen molecules could be demonstrated and
the liquid crystals used as compensators are controlled electronically to produce any polarized
light. Therefore, using PolScope could be a simple and effective label free alternative collagen
imaging modality to implement in clinical and any pathological studies for investigation of
cancerous and non-cancerous tissue samples.72
In addition to the label free SHG and 2PEF microscopy, there also exists staining
techniques that give even more detailed information about the organization of collagen fiber. The
staining technique that is highly in use for collagen fiber imaging is the picrosirius red (PSR)
stain which specifically highlight collagen fiber. PSR stained sample can then be imaged best
using a fluorescence microscope to give information on the orientation and organization of
collagen locally in a specific region of interest. This is a robust and cheaper technique compared
to the multiphoton laser scanning microscopy (MPLSM) that could readily be used for any
pathological studies. However, this labeling technique fails in relying information on how
collagen fiber is influencing changes to the cell environment or how it is being influenced by the
surrounding tumor and normal cells in diseased and normal conditions. Furthermore, although
the staining technique specifically binds to collagen and allows for local quantitative analysis,
the fact that the technique does not allow any analysis to be done in the ECM surrounding the
collagen fiber makes its application limited.73
Another label-free imaging modality that can potentially be used for fibrillar
collagen in cancerous environments is Polarimetry. Polarimetry is a technique that uses polarized
light to measure the different organizational compositions of collagen and other components in
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tissue in diseased and normal conditions. This imaging method could easily be incorporated in a
traditional microscope used by pathologists to look into samples. Unlike highlight advanced
imaging modalities such as SHG, polarimetry provides a cheaper and easily applicable label free
solution to any tumor microenvironment investigation. However, the limitation of this
methodology is that it is a little time consuming, has a lower resolution, and less sensitive to
collagen organization. Polarimetry is not collagen specific, it might not be quite suitable for
collagen specific quantification.74
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CHAPTER 2
MATERIALS AND METHODS
2.1 Methods
2.1.1 Experimental Planning
A total of six low density collagen gel (2 mg/mL) samples, two control and four
experimental (co-cultured breast cancer cell and fibroblast cell lines) were prepared. These
collagen gels are non-scattering which is useful to get F/B directly from the fiber orientation. The
positive control gels contained only decidualized fibroblasts (dBJ) activated by the secondary
messenger cyclic adenosine monophosphate (cAMP); whereas the negative control gels were
seeded with normal fibroblasts (BJ). The fibroblast used here is BJ which is a normal human
foreskin fibroblast taken from a neonatal male.99 Co-cultures of normal fibroblasts and cancer
cells model a non-reactive stroma where co-cultures of activated fibroblasts and cancer cells
model a reactive stroma. In normal stroma, ECM protein production is tightly controlled;
however reactive stroma ECM protein production is dysregulated leading to significant cellmediated collagen synthesis and remodeling. To model normal and abnormal stromal fibroblasts,
we cultured normal and cAMP activated fibroblasts respectively.
In the experimental groups, two types of cancer cell lines were seeded separately in the
cAMP activated fibroblasts containing collagen gel and normal fibroblast containing collagen
gel. The first experimental samples contained dBJ and the MCF7A cancer cell line whereas the
other sample contained the BJ with MCF7A cancer cell lines. MCF7A cancer cells are hormone
responding breast cancer cell lines with human epidermal growth factor 2 (HER2), estrogen
(ER), and progesterone (PR) receptors.100 They retain ideal characteristics particular to
mammary epithelium such as processing of estrogen via estrogen receptors in the cell cytoplasm,
however, it is a relatively less aggressive breast cancer cell line. In the gel model MCF7A_BJ
29

and MCF7A_dBJ, MCF7A cancer cell lines were cultured with normal fibroblasts and cAMP
activated fibroblast to model non-reactive reactive stroma respectively. In the last two
experimental gel models MDA_MB_231_BJ and MDA_MB_231_dBJ, the cancer cell line
MDA_MB_231 were cultured with normal fibroblasts and cAMP activated fibroblast to model
non-reactive reactive stroma respectively. MDA_MB_231 cancer cells are ER, PR, and Ecadherin negative receptors but, they lack the growth factor receptor HER2 which makes it a
triple negative breast cancer cell sub-type.101 MDA_MB_231 are very aggressive cancer cell
lines that often are difficult to treat in clinical diagnosis.
In gels where the cAMP activated fibroblast (dBJ) is co-cultured with either of the tumor
cells, a reactive stromal fibroblast that is more like myo-fibroblasts, interacts with the two
different cancer cells. This demonstrates if the impact of reactive stromal fibroblast on collagen
remodeling is dependent on the tumor cell subtype. In gels where normal fibroblast is cocultured with either of the tumor cells, a non-reactive stromal fibroblast interacts with the two
different cancer cells. These models, therefore, demonstrate the collaborative impact that cancer
associated fibroblasts and cancer cells have on the remodeling of collagen fiber in a tumor
microenvironment. Moreover, the models also demonstrate the difference in the crosstalk
between cancer associated fibroblasts and cancer cells when they associate with different tumor
cell subtypes.
After 72 hour all the samples were fixed with 4% paraformaldehyde (PFA) for Second
Harmonic Generation forward and backward imaging. The sample was also labeled with Cell
Tracker to ease the process of tracking the cell interactions.
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Figure 15: In vitro collagen gel model of normal healthy stromal deactivated fibroblasts – BJ
(A), normal healthy stromal activated fibroblasts – dBJ (B), non-decidualized fibroblasts cocultured with MCF7A (C) and MDA_MB_231 (C) cancer cell lines, and decidualized fibroblasts
co-cultured with MCF7A (E) and MDA_MB_231 (F) cancer cell lines.

31

2.1.2 Image Acquisition
The collagen gel samples were imaged using the multiphoton laser scanning techniques
SHG and 2PEF microscopy. The 2PEF microscopy was used to take the cell fluorescence signal
and the SHG was used to get the intrinsic forward and backward SHG signals from the collagen
network. The Titanium-Sapphire laser was tuned at 750 nm for the cell imaging. A 582/64
bandpass filter was used to epi-detect Cell Tracker fluorescence signals. The laser was tuned at
890 nm for collagen imaging in which a 448/20 bandpass filter was used for the backward
emission detection path and simultaneously the forward SHG signal is collected.

Figure 16: Tilbury lab home built two-photon excitation fluorescence and second harmonic
generation microscope set-up. [Adopted from William Patrick Breeding]102

2.1.2.1 Photon Budget Calculation and Sensitivity Analysis
A photon budget analysis describing the amount of light needed to generate SHG and
2PEF signals is described here. Both optical processes are nonlinear meaning that the intensity of
the emission signals is proportional to the square of the radiation signal. In the analysis the
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number of excitation photons, the number of emission photon, and signal to noise ratio are the
important considerations. The overall efficiency of the system in achieving optimum values for
these three main things is determined by the collection efficiency of the objective lens, the light
transmission & reflection efficiency of other optical components (both in the excitation and
emission path), and quantum efficiency of the detector.
The excitation path is used to estimate the power of the light source and the emission path
is used to estimate the signal to noise ratio. In the excitation path the laser (light source), the half
and quarter waveplates, the dichroic mirror, and the objective lens are considered to calculate the
number of excitation photon (see Figure 1A). The light source for both SHG and 2PEF is a TiSapphire laser. A pulsed light source for the nonlinear optical system. In the emission path the
objective lens, the dichroic mirror, the lens, and the emission filter are considered to calculate the
number of emitted photons. Here, a water immersion objective with numerical aperture of 0.8 is
used for both the excitation photon path and emission photon path. Therefore, the volume in
which the excitation photons go through, and the emission photons leave can be assumed to be
the same.
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Figure 17: Considerations in the excitation pathway (A) to estimate the excitation number of
photon and consideration in the emission pathway (B) to estimate the emitted number of photons
from the sample.
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The specification of each component is:
➢ Olympus LUMPLFLN 40XW Objective
•

Transmission efficiency = 80%

•

Numerical aperture = 0.8

➢ 448/20 bandpass filter
•

Transmission efficiency for wavelength between 438-458nm is 98%

➢ Dichroic mirror
•

Transmission efficiency = 93%

•

Reflection efficiency = 98%

➢ Considering the bandpass filter, DCM, and objective ~76.83% of the emitted photons
reach the detector.
The focal volume (FV) describing the area in the sample where the photon concentration
is higher can be obtained by considering the lateral (𝜔𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ) and the axial (𝜔𝑎𝑥𝑖𝑎𝑙 ) points spread
functions. The ideal point spread function is the three-dimensional diffraction pattern of light
emitted from the laser source in the specimen and transmitted to the image plane through the
objective’s numerical aperture. Both the lateral and axial points spread functions are wavelength
dependent and they can be calculated as follows. The lateral point spread function focuses on the
diffraction pattern of the emitted light in the xy direction as it passes through the back aperture of
the objective lens resulting a 3D interference. The axial point spread function focuses on the
diffraction and interference in the xz direction.

35

𝑧𝑅 =

𝑧𝑅 =

πω2𝑜

𝑧

ω(𝑧) = ω𝑜 √1 + ( )

λ

𝑏

2

𝑧𝑅

θ=

λ

𝑧

2

𝑅(𝑧) = 𝑧 [1 + ( 𝑅) ]

2
πω𝑜
𝑧
Lateral
Point
Spread Function
for NA

=

.

ω(𝑧) = Half Beam Diameter

2
ω𝑜 = Beam Waist 2

=

2 ( Range
𝑧𝑅 =
=Rayleigh

2

)2

𝑧 = Axial Distance
θ = Half Angle Divergence
𝑏 = Confocal Parameter
𝑅(𝑧) = Radius of Curvature
λ = Wavelength
ω𝑅 (𝑏/2) = Rayleigh Half Diameter

36

1
2

2

2
2

➢ Focal Volume (FV)
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The number of photons coming from the light source can be obtained by considering the
number of excitation photon, the reflection efficiency of the dichroic mirror, the transmission
efficiency of the excitation filter, and the transmission efficiency of the lenses in the excitation
path. The number of excitation photon per second required for illumination of the entire field of
view can be characterized by the photon flux. First the number of incoming photons from the
laser are obtained from the total energy of the light source. Then using the power at which the
laser was set to collect the images from the sample, the number of photons per second from the
source can be obtained. Then to get the photon flux first the beam waist of the laser needs to be
calculated from the focal length (f), the excitation wavelength (𝜆), and the beam radius (d) of the
laser. Then the amount of power from the light source in the entire field of view can be estimated
by the photon density using the photon flux and the energy of the photons.
➢ Energy
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The calculated photon flux describing the number of photons striking in the area per
second is greater. But for the wavelength the laser is tunned at, the energy content of each photon
is proportional. There is no absorption of photons and loss of energy in SHG rather the emitted
photons have twice the energy of the excitation photons. Assuming there is no photon
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destruction and considering the bandpass filter, the dichroic mirror, and the objective lens in the
emission pathway, the number of photons leaving the volume can be calculated as shown below
➢ Power Density (Pd)
Pd = (Photon flux)x(Energy of a single photon)
Pd =
Pd = (
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➢ The number of excitation photon entering:
n0source =

n0
R D τEF τobj

n0 source = number of photons from the light source
no = number of photons entering a volume
R D = reflection efficiency of the dichroic mirror
τEF = transmission efficiency of excitation filter
τobj = transmission efficiency of the objective
no = (R D τEF τobj )x(n0 source )
no = ( 98 x 9
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➢ Considering the bandpass filter, dichroic mirror, and objective 76.83% of the
photon reaches the detector
nd =
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➢ Photon counting head: Count sensitivity
Count Sensitivity =

Number of counted pulses (output pulse)
Number of incident photons

Detection efficiency =

Nd
Np

Detection efficiency = Quantum effiecency (η) x Collection effiencency (α)
Count Sensitivity (Detection efficiency) = 72

82s−1 pW −1

2.1.2.2 Sensitivity Analysis
Points to consider for sensitivity analysis
➢ Size: - determines the voxel size with excitation wavelength of 890 nm.
V = (ΔX)(ΔY)(ΔZ)
ΔZ =
ΔZ =
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➢ Intensity: - the signal intensity that is a function of energy flux expressed as energy per
area per time.
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The intensity can also be represented in photons per cm2 s equal to the photon flux
3.066x1026 photons cm-2 s-1.
➢ Spatial resolution: - this is the ability of the microscope to differentiate neighboring
structures as separate. The axial and lateral resolutions can be calculated by considering
the refractive index of water, wavelength, and numerical aperture of the objective.
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➢ The effective area for the photon count head is calculated using the circle 𝐴 = π𝑟 2; it has
a diameter of 5 mm
➢ The pixel size that corresponded to the image pixel is the biggest square that could
possibly fit as shown in the figure below.
The size of the square is
a2 + a2 = D2
2a2 = D2
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➢ The images produced were 512 x 512 pixel and 180 microns for the entire field of
illumination.
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➢ The photon capture efficiency of the first lens
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The calculations above indicate that the exposure of the samples to the calculated photon flux
indicates the maximum photo bleachability of the sample if there was absorption. The
proportional relationship between intensity and photon flux here in the above calculation
indicates that the selected laser power for the SHG wavelength gives a reasonable intensity
within the region of interest. Since signals in SHG are generated without absorption, the variable
that would affect the sensitivity of the system if changed is the power. If the power is increased
to a higher amount, then some areas in the image would be saturated. Since the FSHG/BSHG ratio
is calculated based on the pixel value, saturated areas could affect the resulting value.
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2.2 Image Analysis
After the image acquisition, the processing of images of the biological samples is needed
to extract the necessary information. Image processing can be defined in many ways depending
on the specific research question. In this work, image processing is focused on cell segmentation
for pixel based localized FSHG/BSHG ratio analysis. Image processing for cell segmentation can be
either manual or automated depending on factors such as number of images that needed to be
analyzed, time, speed, accuracy, and consistency. Manual image processing is useful when
identifying a ground truth but, it could be very time consuming and maintaining consistency in
the image processing might be a difficult task to achieve. However, the ground truth obtained
from manual image processing is a great input when programing for automated image
processing.
Image segmentation is one type of biological image processing. In image segmentation,
one image is partitioned into several regions for a specific analysis purpose i.e., further particle
analysis. Biological image segmentation, in particular cell segmentation, can be achieved with
either intensity-based segmentation or other technique. The ultimate goal of segmentation is to
separately extract the needed foreground region from the background. However, depending on
the cell image type there are challenges in cell segmentation. In this work cell segmentation of
the fluorescent cell images is challenged by intensity based segmentation. The cell fluorescence
image is difficult to segment based on intensity alone because of the higher contrast from the
artifacts that appear on the images. To perform effective cell segmentation additional pixel by
pixel segmentation approach is required. Pixel by pixel segmentation is a technique in which
pixels representing particular cell features are selected by highlighting regions and classified as
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one class. Moreover, the pixel-by-pixel segmentation makes the partitioning of the cell regions
easier without needing a rigorous thresholding step.
The outcome from the proper segmentation of the cells is critical to obtain a localized
FSHG/BSHG ratio analysis. The FSHG/BSHG ratio obtained from the bulk image analysis does not
give detail information to answer the research question stated above in this chapter. In bulk
analysis, the alterations on the collagen fiber microstructure are considered from the overall
region of the image whereas in localized analysis the cell induced changes can closely be
assessed. Here, the cell localized analysis is used to look for the distinct collagen remodeling
signatures resulting from the different stromal/tumor cell interactions that are modeled in the in
vitro gels. The specific cell segmentation pipeline described below is developed to answer the
question; are there distinct collagen remodeling signatures induced from the interactions between
decidualized fibroblast with tumor cells, and the interaction between normal fibroblast with
tumor cells that contribute to metastasis?

2.2.1 iLastik Cell Segmentation
The cell segmentation process was carried out using the software iLastik which is a
machine learning based image analysis software. iLastik software is a deep learning package
based on convolutional neural networks enabling pixel and object level classification.103 The
neural network is trained for the pixel-by-pixel semantic segmentation followed by object
classification. Semantic segmentation here refers to the grouping of the cell features, other
artifacts, and the background to the same pixel class. Differentiation of the foreground and the
background classes was first completed manually using selected images which then were fed to
the network as ground truth. Then batch processing can be completed for all the images. Prior to
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the image segmentation, cell image pre-processing was completed to generate Max Z-projection
of cells from the optical sections containing the same cell. This projection considers the
maximum pixel intensity in every optical section to produce one image. The projection is
selected because the produced image shows all the cell features presented in every slice (as
shown in Figure 18) compared to average and minimum intensity projections. This was a very
applicable approach for this work because in the output image the lower and higher intensity of
certain cell feature in the optical sections is balanced. In optical section where cells have higher
intensity, semantic segmentations can easily be performed but those optical sections with lower
intensity are quite challenging even for pixel-wise segmentation. Additionally, during batch
processing, cell features with low intensity mistakenly get classified as part of the background
class rather than the foreground class. Since the aim of the cell segmentation is to create cell
mask for the depth independent FSHG/BSHG analysis, taking this max projection would make sure
that every cell feature is considered. Furthermore, the localized FSHG/BSHG analysis is depth
independent and only considers pixel value of the collagen forward and backward images so the
pixel values from the cell fluorescence does not affect the final result.
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Figure 18: Maximum intensity Z-projection of 2PEF cell images prepared to be used as an input
for cell segmentation.
In iLastik there are several workflows but the two selected workflows in this work are
Pixel-Classification and Object-Classification. Pixel-Classification workflow produce sematic
segmentation of images in which the user defines each class by selecting the different desired
number of classes using different colors (Figure 19B).104 iLastik then gives the probability map
by estimating every pixel in the image based on the pixel values in the user labeled class (Figure
19C). However, the probability map only separates the foreground and the background based on
the pixel annotation which does not include instance segmentation. Instance segmentation is
process in which every object in an image is detected, segmented, and classified.105 In instance
segmentation different object classes are formed where each cell is treated as a single entity to be
classified into different population. The pixel wise semantic segmentation fails in distinguishing
between classes of different object characteristics because it treats all the cells in the optical
section as single entity. As the cells in one optical section are in different size and shape, the
probability map from the pixel segmentation needs to be further segmented out with object
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classification. This is also beneficial for later batch processing in object classification. In object
classification, first, the imported probability map is smoothed with a gaussian filter of sigma 5.0
(this can be selected in the feature map section) and Thresholded. The different object classes
could then be selected to train the network by simply color coding the different objects. The
output object prediction image is then exported to ImageJ for further analysis (see Figure 19D).

Figure 19: Process flow diagram (A-E) for semantic segmentation of cells using pixel + object
classification.
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2.2.2 F/B Ratio Analysis on Image J
Segmented cell images imported from iLastik were loaded on ImageJ for the next image
analysis process to obtain the localized FSHG/BSHG ratio (see Figure 20A). First, the imported
image, which has foreground 1-pixel and background 2-pixel range, was converted into a binary
image of foreground pixel 0 and background 255 pixel (Figure 20C). The main advantage in
converting all iLastik imported images to binary image is to allow easy manipulation of the cell
regions for the desired analysis without needing to worry about Thresholding. All the binary
images were converted to mask which converts the images into black (background) and white
(foreground) based on the threshold setting in the images. The masks were then added to ROI
manager to count the individual cells for a per cell base localized analysis. Before further
analysis was performed the cell masks were dilated by 10 pixel (3.5 µm) for the localized
analysis (Figure 20B). Once the cells in the original mask and the dilated mask were counted the
images were converted to a 32-bit image. The 32-bit masks (original and dilated) were processed
with image math to change the background pixel to not a number (NAN) (Figure 20D-E). This
way the result table represents solely the FSHG/BSHG in each ROI without needing to worry about
the background pixel value from the cell mask being considered in the image math.
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Figure 20: Fiji image analysis process (A) preparing cell ring ROIs (B-E) for localized F/B ratio
calculation.
The collagen images from the forward emission and the backward emission were
analyzed separately (see Figure 21) from the cell segmentation until the final image
multiplication step. First, the forward (Figure 21A) and backward (Figure 21A’) image stacks
corresponding to the cell stack max Z-projection were loaded on ImageJ. The forward (Figure
21B) and the backward (Figure 21B’) stacks were Thresholded with Li thresholding algorithm
separately to filter out noise before dividing the stacks (Figure 21C & 21C’). The resulting image
(Figure 21D) from the image division was then multiplied with the cell ROI image. Refer to the
Appendix for the FIJI macro.
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Figure 21: Image operation process for the forward and backward SHG images division. Image
math process presenting the multiplication between the FSHG/BSHG ratio for the cell localized
analysis.
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2.2.3 F/B Ratio Statistical Analysis on R
In Excel, the average FSHG/BSHG ratio of every cell was calculated from the number of
slices in which the cell max z-projection was taken. This value represents the average FSHG/BSHG
ratio of each individual cell counted in the entire cell ring ROI slice. The average FSHG/BSHG ratio
was then imported in R for the boxplots and the statistical analysis. To compare the FSHG/BSHG
ratios of the desired samples the Wilcoxon rank sum test was performed. The Wilcoxon rank
sum test is a non-parametric alternative to the two-sample t-test that is solely based on the
ranking the samples. This test is selected because the samples that are being compared are
independent of each other and some of the samples are not normally distributed. In this test, the
FSHG/BSHG values are ranked to see whether they are evenly distributed or not across both
populations, therefore, the original values are not directly considered. The p-value obtained
assesses the probability of the null hypothesis which is the two populations are the same. For pvalues <0.05 relates to the statistically significant difference in values across the two
populations.

2.3 Result
2.3.1 Comparison of FSHG/BSHG Ratio of Control Samples BJ and dBJ

The BJ fibroblast cells in the collagen gel model were stromal deactivated cells. And the
dBJ fibroblast cells are the stromal activated fibroblasts with cAMP. Stromal activated
fibroblasts that differentiate into myofibroblasts are useful for extracellular matrix remodeling
for purposes such as wound healing, tissue inflammation etc. (as explained in Section 1.2.2). The
(+) control collagen gel containing the decidualized (activated) fibroblasts (dBJ) shows an
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increased FSHG/BSHG ratio result. This increase indicates that there was a microstructural
reorganization of collagen fibril packing. As discussed above in section 1.3.3, the increase in
FSHG/BSHG ratio comes from the phase matching effect and the fibrillar packing in the collagen
environment. Based on visual observation of the resulting FSHG/BSHG ratio image, it seems like
there is higher collagen density in both (+ control) dBJ and (- control) BJ near the cell boundary
in the ROIs, but remodeling as expected is seen highly in the activated fibroblast. However, there
was not specific collagen density quantification done which can be part of the future wok. The
non-decidualized (deactivated) fibroblasts (- control) on the other hand did not induce
remodeling in the collagen fiber compared to the decidualized fibroblasts (+ control). This result
is also supported by the obtained lower FSHG/BSHG ratio; dBJ sample has higher FSHG/BSHG ratio
than BJ sample. The FSHG/BSHG ratios calculated assess collagen signatures locally in both the
activated and deactivated fibroblast environments. The box plot (Figure 22) shows these
differences in values for both control samples. The non-parametric test, Wilcox-rank sum test
performed to compare the values of the FSHG/BSHG ratios of both samples gives p-value <0.05
showing a statistically significant difference. From this we can understand that reactive stromal
cell remodel collagen even without the presence of tumor cell.
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Figure 22: The control gel model containing activated fibroblasts (dBJ) have higher collagen
remodeling effect as seen in the heat map (A) than the control gel containing deactivated
fibroblast (BJ), therefore has increased FSHG/BSHG (B).
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2.3.2 Comparison of FSHG/BSHG Ratio of MCF7A and Inactive vs. Active Fibroblast
The experimental sample MCF7A_BJ contained the MCF7A cancer cell lines and the
non-decidualized (stromal deactivated) fibroblasts which were left to interact with the cancer
cells. This condition recapitulates the interaction between a cancer associated fibroblast and the
cancer cell lines to induce remodeling on fibrillar collagen. The experimental sample
MCF7A_dBJ contained the MCF7A cancer cell lines and the decidualized (stromal activated)
fibroblasts. This condition recapitulates the interaction between the cancer cells and the stromal
activated fibroblasts. The FSHG/BSHG ratio obtained for the MCF7A_BJ sample has a larger
median value than MCF7A_dBJ (Figure 23). This result shows that there is different
microstructural reorganization of collagen fibril in tumor microenvironment where stromal
inactive fibroblast (BJ) and MCF7A are interacting. This shows that the degree of remodeling in
ECM protein by the interacting fibroblasts and MCF7A cancer cell lines varies based on the
stromal cell condition (reactive vs. normal). Therefore, in MCF7A_BJ there is larger fibrillar
packing highly ordered in the size scale of the SHG wavelength (as it resulted higher FSHG/BSHG
ratio) compared to MCF7A_dBJ. The crosstalk between the stromal active fibroblast and the
ER+ cancer cell line does not seem as aggressive in imposing greater microstructural remodeling
in collage fiber compared to tumor/inactive fibroblast interaction. Qualitatively the collagen fiber
appears to be highly straightened and aligned parallel to the tumor cell boundary in
MCF7A_dBJ. However, the smaller FSHG/BSHG ratio shows that the fibrillar packing in the
microstructural orientation is not quite ordered to the size scale of SHG wavelength.
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Figure 23: A. Heat map showing higher remodeling in collagen when MCF7A interacts with
stromal activated fibroblasts than decidualized fibroblasts, therefore it results higher FSHG/BSHG
ratio (B).
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2.3.3 Comparison of FSHG/BSHG Ratio of MDA_MB_231 and Inactive vs. Active Fibroblasts
The experimental sample MBA_MB_231_BJ contains the cancer cell line
MDA_MB_231 and the decidualized (stromal deactivated fibroblast) that are left to interact with
the cancer cells. Again, in this environment the interaction between the aggressive cancer cell
line and cancer associated fibroblasts is recapitulated. The experimental sample
MDA_MB_231_dBJ contains the aggressive cancer cell line and the stromal activated
fibroblasts. This sample is where the remodeling in the fibrillar collagen by MDA_MB_231
cancer cells and the not specifically cancer associated but activated fibroblast is recapitulated.
The remodeling induced on fibrillar collagen due to these interactions is quantified by the F/B
ratio.
The F/B ratio obtained for MDA_MB_231_BJ does not show a normal distribution in the
values. This result is demonstrated in the heat map on the ROI image in which some areas are
hotter than others (Figure 24). The hotter regions are associated with higher F/B ratio due to the
higher fibrillar packing in the order of the SHG wavelength. The remodeling that activated
fibroblasts induce on fibrillar collagen is highly characterized by pulling the fibers towards the
cell surface.106 The model here sowing the remodeling induced by cancer associated fibroblast is
a single mode of potentially multiple modes of remodeling i.e proteolytic degradation, tension
mediated linearization, and collagen synthesis.107,108 In the image, it appears as if areas of higher
collagen density surrounding the tumor border have a characteristics of shorter collagen fiber
segments oriented perpendicularly to the tumor cell boundary. As part of future work, the
fibrillar alignment can be quantified using a curvelet-based approach in addition to the localized
F/B analysis of the microstructural fiber orientation.
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The F/B ratio obtained for MDA_MB_231_dBJ does show a normal distribution in the
values with a relatively higher median than MDA_MB_231_BJ. In this tumor
microenvironment, the cancer cells, and the stromal activated fibroblasts (not necessarily cancer
cell activated) both induce remodeling in the collagen surrounding them. Likewise, to the tumor
microenvironment with cancer associated fibroblasts, there is higher collagen microstructural
reorganization. Qualitatively it also appears that the collagen fibers are shorter in length but more
spread out in their orientation near the tumor boundary. Based on a prior study, Bruke et al,
demonstrated that higher FSHG/BSHG is associated with longer distance tumor migration, the
localized F/B analysis for both MDA_MB_231_BJ and MDA_MB_231_dBJ presents tumor
associated collagen signatures that seem to not favor tumor migration.109 These collagen
signatures detected by the emission directionality ratio of SHG are associated with metastatic
conditions.71 The remodeling behavior of the aggressive cancer cell MDA_MB_231 is different
when cancer associated fibroblasts versus stromal activated fibroblasts are present in the
environment.
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Figure 24: MDA_MB_231 cancer cell line induces remodeling differently co-cultured with BJ
versus dBJ (A). Although the F/B ratio of MDA_MB_231_BJ does not sow a normal distribution
statistically, it still has relatively lower median than MDA_MB_231_dBJ (B).
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2.3.4 Comparison of FSHG/BSHG Ratio of All dBJ Samples and BJ Samples
The localized F/B ratio analysis for the decidualized control and experimental groups has
p-value >0.05. This result from the non-parametric Wilcox-rank sum test shows that there is no
statistically significant difference between their F/B values. In these samples remodeling is
induced both by the decidualized fibroblast and the two cancer types simultaneously. This result
shows that a lower F/B ratio is associated with the presence of stromal activated (decidualized)
fibroblasts in the tumor microenvironment. This low value is related to larger ∆K which
describes the degree of phase mismatching and this shift in F/B could be due to on-going quasiphase matching.93 As described in Section 1.3.3, the F/B ratio is comprised from the subsequent
forward and backward emissions from the dipole moment in the fibrillar assembly. The different
collagen signatures from the remodeling are results of the induced reorganization of the fibers
from their interaction with the cancer cells. The low F/B ratio quantifying this reorganization
also gives information on the dipole moment organization within the collagen molecules in the
fibrillar assembly.
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Figure 25: TME containing decidualized (activated) fibroblast and both cancer cell lines
(MCF7A & MDA_MB_231) induce disordered fibrillar packing in the collagen remodeling.
(lower F/B). Decidualized fibroblast & MCF7A in TME are characterized by more packed
and aligned smaller diameter fibers. Decidualized fibroblast & MDA_MB_231 in TME are
characterized by higher collagen deposition.
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The localized F/B ratio analysis of the non-decidualized control and experimental samples
have p-value <0.05. This result from the non-parametric Wilcox-rank sum test is showing a
statistically significant difference between the control sample with a stromal deactivated
fibroblast and the experimental sample with the two cancer cell lines. In the MCAF7A_BJ
sample, where the stromal deactivated fibroblasts are actively interacting with the cancer cells, a
higher F/B ratio value is obtained. In this scenario, the collagen signature is result of the
reorganization by the cancer associated fibroblasts and the cancer cells. In this signature the
dipole moment in the molecular assembly has lower degree of phase mismatching. The
alignment and packing of the fibers here are ordered to the size scale of the SHG wavelength in
the axial direction.
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Figure 26: TME containing non-decidualized (deactivated) but cancer associated fibroblast
& either MCF7A or MDA_MB_231 had a higher FSHG/BSHG ratio. In TME with MCF7A &
cancer associated fibroblasts collagen is highly remodeled in which less randomly packed
fibers are aligned. In TME with MDA_MB_231 & cancer associated fibroblasts collagen
remodeling is characterized by fibers pulled towards the cell.
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CHAPTER 3
DISCUSSION AND FUTURE WORK
3.1 Discussion
In a previous study completed by Bruke et al109, different collagen microstructures were
modeled to assess the behavior of tumor cells, however, the tumor cells themselves were not
responsible for the remodeling. In their study it was shown that in tumor microenvironment
where FSHG/BSHG ratio is higher there is increased tumor motility. From this work, MCF7A_BJ
sample having a greater F/B ratio than MCF7A_dBJ, shows that if the cells were being tracked
there could be a possibility for the tumor microenvironment to be supportive of their motility.
Furthermore, the non-parametric Wilcox-rank sum test performed to compare the FSHG/BSHG
ratio obtained for the MCF7A_BJ and MCF7A_dBJ shows a statistically significant difference
with a p-value <0.05. In this condition it can be understood that MCF7A breast cancer subtype is
most likely to metastasize in a non-reactive stromal cell environment where they are interacting
with stromal deactivated fibroblasts.
Comparing the F/B ratio of MCF7A_BJ to MDA_MB_231_BJ, the reorganization of
fibers locally near the boundary of the cells is hotter in majority of the areas as shown in the heat
map in Figure 24. Whereas in MDA_MB_231_BJ, the F/B ratio heat map shows different ranges
of values in FSHG/BSHG ratio. This difference in F/B ratio depicts the fibril packing that SHG is
sensitive to. The detected tumor associated collagen signatures in this localized F/B analysis is a
very promising result to differentiate between all the presented conditions. Using this results the
characteristic signatures resonating to the remodeling by the two different cancer cell types, by
stromal activated fibroblast, and the stromal deactivated fibroblasts was understood.
Furthermore, these results also show how the two difference cancer cells induce remodeling
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when they are along with stromal deactivated (cancer associated fibroblasts) and stromal
activated fibroblasts. The two cellular interaction types (reactive stroma vs non-reactive stroma
with cancer cell) have different remodeling outcomes in their surrounding collagen fiber
depending on the tumor microenvironment. The cancer cells themselves behave differently in
remodeling fibrillar collagen around them when they are interacting with either of the fibroblast
types. Relating F/B ratio from these signatures with previous studies completed on tumor
motility based on F/B ratio variation, it can be claimed that the higher F/B ratio favors migration
of tumor cells to secondary location.
SHG, as collagen specific imaging, is a promising tool to implement in a clinical
diagnosis. This light-based technology gives deeper insight of the tumor microenvironment.
Deeper understanding of the interaction between cancer cells and stromal cells is very important
to identify the proper preventative action that needs to be taken to minimize the chance of the
spreading of tumor. For that matter, several researchers have shown that SHG is a promising tool
to be used for better patient prognosis in cancer studies.110–113 As briefly explained in Chapter 1,
despite the presence of increased diagnosis in developed countries, the mortality rate of breast
cancer has not decreased. The focus of these advanced diagnostic techniques is to reveal the
unseen detail in tumor microenvironment. The results from this diagnosis are then used to
determine the necessary treatment depending on the stage of the breast cancer. However, results
from overdiagnosis can potentially lead to overtreatment. Therefore, the transition of advanced
pathological instruments such as SHG from the bio-photonics society to the clinical team is
impactful in minimizing overdiagnosis. For this bridge between bio-photonics lab research and
clinical diagnosis to be successful the replication of laboratory testing protocols is crucial. The
different biological models used in bio-photonics laboratories simulating a particular health
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problem show the great potential in these technologies that is worth of translating to the clinical
environment. Some of the current competitive instruments in the bio-photonics research world
that had shown repetitive promising result in their tumor microenvironment study are listed in
the following section.

3.2 Analysis of Imaging Techniques in Clinical Environments
In the field of medical imaging, the two main categories are optical imaging device and
radiological imaging device. Optical imaging devices are used in a lot of primary diagnosis,
point-of-care treatments, and in everyday medicine. Optical imaging is underestimated compared
to radiological imaging, but it is a crucial component of healthcare. The advantage of optical
imaging can be seen from two perspectives: clinical use and market analysis. A recent market
analysis by Dr. Brian Pogue published on SPIE in 2018 has shown that compare to radiological
imaging, optical imaging has a greater use in everyday medicine.114 The market analysis shown
in the pie chart below (Figure 27) also shows that optical imaging has a bigger investment than
radiological imaging in the global market. This pie chart shows that optical imaging plays the
dominant role in the medical imaging market. However, as the market analysis of biophotonics
presented by Stephen G. Anderson, SPIE’s industry and market strategist, the biggest challenge
in photonics technology economic analysis is lack of data.115
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Figure 27: Global market evaluation on optical and radiological imaging between 2015-2017 in
US dollar. [Adopted from Pogue. (2018)] 114
In the field of photonics, optical imaging tools are designed and used for a wide range of
biomedical research to investigate several biological problems. These optical imaging devices
most of the time are custom designed, and home built for specific in vivo or in vitro studies.
Often these devices are built in an open space to modulate one standard design to several
imaging techniques by simply switching some components. This method relatively is cost
effective when compared to developing one optical imaging medical device. Most of the time
these imaging modalities are built in research laboratories that are not necessarily clinical
environment and so the open space development provides flexibility. If these devices are to be
introduced to a clinical environment, they need to be built in a closed box. Furthermore,
developing the device to be simple model but technologically complex enough to bring solution
to a particular clinical problem impacts the adoption of the device to clinical use greatly. Another
key consideration to take when developing the model is that it should be easy for the end user to
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operate. Unnecessary complications on the model or requirement of special training to use the
device most of the time are great reasons for doctors, nurses, or other direct user healthcare
professionals to reject using the device. The merging of virtual reality with microscope has led to
the development of virtual microscope 20 years ago which contributed to the advancement of
digital pathology.116

3.3 Current Slide Scanning Techniques For Clinical Use
Digital pathology has been playing a crucial role in the efficiency of clinical diagnosis
since its introduction 20 years ago.116 Since then, there has been several companies that have
been investing in producing slide scanning devices for clinical use. The current highly used
scanning devices in laboratories are whole slide imaging device. Philips Intellisite Pathology
Solution is the first whole slide imaging device to get the US Food and Drug Administration
510(K) clearance for clinical use without the need for premarket approval.117 Whole slide
imaging devices could either be manual or automated with the manual device being the cheaper
option. Although the manual whole slide imaging device are efficient and cost-effective, the time
consumption relative to the automated whole slide imaging devices is longer. The relatively
higher cost for automated whole slide imaging devices can be compromised by the greater
advantages it offers especially the speed in image capturing. Overall, the introduction of whole
slide imaging in digital pathology enhanced diagnostic ability, quality image production for
pathological assessment, advanced imaging, efficient time use, ability to process more slides, and
reduced physical data storage.118 Furthermore, operational cost analysis completed pre and post
implementation of whole slide imaging device has shown a significant saving in the overall cost
as shown in Figure 28 below. The current pricing for whole slide scanning imaging ranges from
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$30k - $250k and the analysis shown in the graph below presents a saving of > $270k per year
and $1.3 million in the overall five years analysis.118,119

Figure 28: Operational cost analysis of whole slide imaging device considering every party that
is involved from vendor to user (A) and overall cost saving analysis within a five year range (B).
[Adopted from Lucas et al. (2021)]105
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The biggest determining factor when brining a new medical device to the market is that it
should not be more expensive compared to an already existing device. Therefore, optimization of
cost of production is very critical for companies to consider. Not only cost of production is a
determining factor but also cost for clinical trials and FDA approval is an additional constraint.
Then, the challenge for the introduction of new optical imaging device to the market begins with
clinical trial cost. Once all these steps are passed adoption of the device could be challenged by
end users mainly pathologists (as a slide scanning microscope is considered as a pathological
device), insurance companies (this takes the amount of money patients need to spend for the
procedure into consideration), reimbursement strategies (if the device is to be adopted for clinical
use this needs to be considered), and several market penetration constraints.

3.4 Advantages and Limitations of Digital Pathology
3.4.1 Advantage of Digital Pathology
-

The Pathologists could easily communicate with other specialists from all over very
quickly when reviewing patient’s slide.120

-

The steps in digital pathology are simple and easy: scan, digitize image, display. The
scanning speed and the high-resolution digital images provides Pathologists with
detail information within a reasonable time frame.121,122 The digitization of the images
will minimize the need for physical storage of sample slides. Once the images taken
from the slide scanning are digitized the images are saved and can be reviewed again
without the need to view it under conventional microscope. This adds the value of
being able to refer to patient slides at anytime it is needed. The displayed image has a
spatial resolution in which the pathologist can view every detail in the slide.
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Furthermore, this could also result in the development of computational models to
assist the Pathologist in reviewing the slide for any cell analysis. Although, human
trained personnel are always more efficient than computers, challenging tasks such as
cell segmentation and particle analysis that are time consuming can transition from
human to a trained computational model.103,123,124 This is not to say that machine
learning can fully replace trained and experienced personnel, but the model can be
objective and consistent to aid the work force.
-

The current strongly growing digital pathology is whole slide imaging technology
permits the collaboration of multiple specialized and sub-specialized people in
reviewing a patient slide to decide on the needed treatment. This especially is very
useful at times of public health emergency.119,125

-

The digitization of tissue section scans helps the pathologist to analyze any tissue
section with a greater resolution to get detailed information.126

-

The advancement in this technology not only helps the clinical diagnosis but also
medical research and preparation of standardized teaching materials for different
disease states.

-

In addition to the standardization of digitized tissue section analysis, whole scan
imaging also benefits in quality assurance, retrieving data for electronic medical
records, and improving the communication across institutions in patient treatment.127
This great clinical advantage comes from the fact the digital pathology cuts the need
for physical transportation of tissue slides between expertise.

-

Digital pathology is also useful for preparing educational materials using actual
patient tissue samples instead of cartoons which aids the learning team greatly.
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Furthermore, digital pathology brings students closer to clinical pathological samples
for direct interactive learning without the need for physical slides.128
-

Digital pathology has a greater benefit for scientific research as it serves as a main
source of digital images for the development of computational models for image
analysis techniques applicable for clinical use.

-

Applications of deep learning in academia has been greatly benefiting the research
world but now the introduction of digital pathology helps in integrating computer
aided diagnostics in pathological analysis in routine work. There are already
companies that are working to develop AI technology for clinical use and have gotten
FDA’s approval.129 The use of digital pathology helps in producing more digital
images from the different disease states which serves as an input for the
computational pathology to make generic models to analyze the images.130,131 The
development of generic computational models to analyze digital images containing
varied defective areas can enhance the efficiency of Pathologists. As a final step all
the Pathologist has to do a confirm the detected areas by the computational model are
the correct defective region.

3.4.2 Limitations and Challenges of Digital Pathology
-

Initial high cost when first implementing digital pathology device is the number one
challenge for laboratories.132

-

The price of digital pathology instruments is higher than having a simple light
microscope that has traditionally been the gold standard to use in pathological labs.
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The involvement of insurance companies and other governmental healthcare agencies
to reimburse the clinic for these instruments is a critical need by any hospital.
-

Adjustment of workflow to incorporate digital pathology to the already existing
system could be challenging to the lab environment and to the team of experts’.133,134

-

Although digital pathology has been discovered more than a decade ago, its adoption
for clinical use is not growing at a faster rate. One of the many challenges in the
adoption is the training of Pathologists to transition to the newer technology to
maximize their productivity from the tedious traditional gold standard technique. The
training by itself is challenged by the Pathologist’s self-assessment and the ability to
learn faster. Just the replacement of microscope itself could challenge the Pathologists
mentally since most experienced pathologists are old and are not prone to big
changes. However, there are several laboratories sharing outcome and the process of
transitioning to digital pathology.118,132–136

-

As digital pathology device are instruments that contain a relatively complex design
than the simple traditional light microscope, any software and hardware issue could
affect the workflow.

-

Digital pathology requires higher capturing efficiency to digitalize, distribution, and
storage of whole slide images. According to the current existing network and storage
this might be challenging for every clinic to adopt digital pathology.

3.5 Market analysis for whole slide imaging
Since the introduction of virtual microscope, digital pathology has been capturing the
attention of the pathology device market. Digital pathology has now more than five competitive
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companies that are highly involved in the market. This highly growing industry is expected to
reach $1,582 million USD in whole slide imaging device market.137 Analysis from a large health
center after implementing digital pathology in full scale for five years has shown $18 million
cost saving and same analysis in University Health Network in Canada shown $CA 131,000 cost
saving per year.138,139 In addition to cost effectiveness, a critical component of the market
analysis for whole slide imaging is the regulatory component. FDA considers whole slide
imaging devices either as class III with a pre-market approval regulatory path or recently as class
II de-novo applications for limited use in immunohistochemical stained sampels.140,141 Also,
FDA released a guideline for testing of the whole slide imaging devices as they get introduced to
for clinical use.142 Simplifying the steps in the FDA approval process for the whole slide
scanning imaging devices is a determining factor for the development of market for digital
pathology and also for the acceptance of the devices by pathologists. The development and
approval of different image analysis techniques for pathologists to use, however, is increasing
the adoption of digital pathology. Getting the most information out of a hematoxylin & eosin
stained sample image is what pathologists care most about so developing this as cost effective
and simple as possible would significantly increase the market.143 SHG as a label free slide
scanning imaging technique adds a great value to the competitive digital pathology market if it
can be commercialized in a cost effective way.

3.6 Translational research for the commercialization of SHG
In translation research where inventions go from bench to bedside, there are different
kinds of considerations to take. Most of the time the work starts in academia research then it
transfers to industry for development. However, often the culture and the work model of
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academic research and industrial development go in their own separate ways. This gap between
academic research and industrial development needs to be bridged with clinical consultation.
Academic research completed without the cooperation with clinical needs and industrial business
reality is challenged to successfully proceed in its translation to the real world. In the translation
from academic research to industry then to clinic, there are three main factors: the type of topic,
maturity of the idea (completion of basic research and proof of concept before transferring to
commercial owner), and exist strategy (proper transferring to commercial owners and continuing
connection).144 It is very important for the bio-photonics academic research team to consult with
these two sectors if there ideas are medically applicable beyond academic laboratory.

3.6.1 Strength, Weakness, and Opportunity For Commercialization of SHG
3.6.1.1 Strength
SHG, as a slide scanning technique, belongs to the family of digital pathology
technology. The current whole slide imaging techniques that are in clinical use do not have
specificity in terms of sensitivity to any microstructures within the section of the imaged tissue.
The whole slide imaging devices mainly simplify the tedious work in a pathologist lab but not
necessarily advance the detection of changes in diseased and healthy tissue. The pathologist
would still need to spend time looking into the images deeply for pathological assessment.
Although there are some artificial intelligence programs that are being developed and approved
by FDA for clinical use by companies such as Paige,145 the main focus is to help the pathologist
identify suspicious areas faster and effectively. But imaging techniques that are sensitive to
microstructural changes like SHG further simplify the pathological analysis process. A simple
image analysis pipeline as shown in this work could be developed to differentiate between cases.
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In modern life science, powerful imaging modalities used to study tumor
microenvironment mostly require some form of labeling. SHG being a label free imaging
modality is one of its strengths that makes it stand out from other techniques. The ability of SHG
to give information on microstructural organization from the intrinsic property of a specific
molecule is its great quality in tissue characterization and diagnostics. Recent study has shown
that quantitative SHG analysis is regarded as a great addition to the qualitative morphological
analysis of labeled tissue samples imaged using a bright field microscopy (a gold standard
technique).146 The ability of this nonlinear optical imaging techniques to easily be incorporated
into the traditional histopathological protocol advances the diagnostics process for cancer
patients. Furthermore, studies completed by Shirmanova et al. and Wu et al. have showed that
SHG can be used to characterize tumor associated collagen alterations after chemotherapeutic
treatment.147,148 The outcomes from these studies show the strength in SHG imaging to serve as a
diagnostic tool to differentiate between treated vs untreated tissue samples as well as different
fibrotic responses in normal and treated carcinoma tissue. Moreover, a review completed by
James et al. showed the promising future of SHG to be used as a diagnostic tool even beyond
cancer.149

3.6.1.2 Weakness
SHG is a powerful optical tool that if built based on clinical standards, it can significantly
improve cancer diagnostics. One of the limitations in SHG that could possibly challenge the
production of SHG for clinical use as a slide scanning device is that it has expensive cost of
production. For SHG to be commercialized as a whole slide imaging technique, its production
cost must fit in the estimated global whole slide imaging device market. The market of digital
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pathology is at a growing rate, however, the cost of production for highly sensitive whole slide
imaging instruments like SHG may be one reason to why it may slow down in its
commercialization. However, this is not a discouragement for the possible future in SHG
commercialization for clinical use.

3.6.1.3 Opportunity
Applications of SHG that are being shown in several biomedical research is an
enlightening opportunity to commercialize SHG for clinical use. Companies like
HarmonigenicTM Corporation are working on bringing SHG from lab to clinic to improve early
treatment administration for people who are at early stages of cancer and those who have higher
risk for metastatic cancer.150 The promising result they have accrued from using SHG to analyze
primary tumor biopsies provided a prognostic information in ER+ and lymph node negative
breast cancer patients.110 Seeing companies like this working towards introducing SHG for
clinical use coupled with the growing market for whole slide imaging devices in the coming
years shows possible opportunities for SHG commercialization. A study completed by Grubbs et
al. showed the possibility for the production of a low-cost beam scanning SHG.151 Although in
this research the produced SHG microscope was used in agrochemical materials imaging, this
still shows the possibility for making a low cost SHG.
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APPENDIX
FIJI sample macro
// A for loop to calculate the F/B ratio.
for (i=0; i < Cell_Zproject.length; i++) {
image=Cell_Zproject[i];

// loads the segmented cell stack corresponding to FBSHG stack of each area.
filename1= image + "BJC_Stack.tif";
open(filename1);
run("Enhance Contrast...", "saturated=10");

setAutoThreshold("Li dark");
run("Convert to Mask");
rename("mask");
run("Remove Outliers...", "radius=5 threshold=50 which=Bright");

selectWindow("mask");
run("ROI Manager...");
run("Analyze Particles...", "clear summarize add");
run("Divide...", "value=255");

run("32-bit");
setAutoThreshold("Li dark");
run("NaN Background");
rename("Cell");
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// Loads the folder containing the forward stack images.
filename2=F_stack + ".tif";
open(filename2);
rename("Forward");
setAutoThreshold("Li dark");
run("Fire");

// Loads the folder containing the backward stack images.
filename3=B_stack + ".tif";
open(filename3);
rename("Backward");
setAutoThreshold("Li dark");
run("Fire");

// Image math
imageCalculator("Divide create 32-bit stack", "Forward","Backward");
selectWindow("Result of Forward");
imageCalculator("Multiply create 32-bit stack", "Result of Forward","Cell");
roiManager("multi-measure append summary stack");

saveAs("Result", base_path + "\\results\\FB_" + ".csv");
selectWindow("Results");
close();
run("ROI Manager...");
run("Close");
close("*");
}
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